BioCentury | Jul 17, 2020
Finance

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

Biotechs on STAR suffer amid broader sell-off As concerns about the COVID-19 outbreak and a mixed recovery outlook rattled stocks traded in Shanghai, biotech stocks on the STAR exchange generally fared worse than the Shanghai...
BioCentury | Feb 21, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BioCentury | Feb 19, 2019
Company News

HaiHe forms joint venture with CSPC, narrows focus to oncology

Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed. HaiHe...
BioCentury | Dec 7, 2009
Strategy

Two Genomic Sagas

Despite being in the vanguard of the genomics revolution, deCode Genetics Inc. struggled to take up the drug development mantle as others have done. Now, having raised just over $1.1 billion from the sale of...
BioCentury | Nov 23, 2009
Company News

deCode cardiovascular, diagnostic, genomics news

deCode filed for Chapter 11 bankruptcy to facilitate the sale of its assets. The company plans to sell its Islensk Erfdagreining subsidiary to Saga Investments LLC. Islensk conducts deCode's human genetics research, manages its population...
BioCentury | Nov 18, 2009
Company News

deCode files for Chapter 11

deCode genetics Inc . (NASDAQ:DCGN) filed for Chapter 11 bankruptcy to facilitate the sale of its assets. The company plans to sell its Islensk Erfdagreining subsidiary to Saga Investments LLC. Islensk conducts deCode's human genetics research,...
BioCentury | Oct 20, 2008
Company News

deCode cardiovascular, inflammation, genomics news

deCode hired the Stanford Group Co. to assist in evaluating strategic alternatives, including identifying buyers and partners for non-core business units, programs and IP. In its 10-Q filed on Aug. 11, deCode said its core...
BioCentury | Jul 21, 2008
Clinical News

BGC20-1531: Phase II start

Early next year, BTG will begin a Phase II trial. The company licensed rights to BGC20-1531 from Asterand in 2006 (see BioCentury, Feb. 6, 2006). Asterand plc (LSE:ATD), Royston, U.K. BTG plc (LSE:BGC), London, U.K....
BioCentury | Jul 7, 2008
Clinical News

DG041: Phase IIa data

In a Phase IIa trial in 42 healthy volunteers, DG-041 as monotherapy or in combination with Plavix clopidogrel or clopidogrel and aspirin did not significantly increase bleeding time vs. placebo. Compared with placebo, DG-041 as...
BioCentury | Mar 24, 2008
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/20 cls Affymax (NASDAQ:AFFY) Summer Street Carol Werther Price target Buy -13% $13.78 Werther lowered her target to $32 from...
Items per page:
1 - 10 of 17